Difference between revisions of "Team:ETH Zurich/Achievements"

 
(31 intermediate revisions by 5 users not shown)
Line 15: Line 15:
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
 +
 +
<div class="highlightBox">
 +
<h3>Awards and Medals</h3>
 +
<p>At the Giant Jamboree in Boston, MA, end of September 2105 our project <b>MicroBeacon</b> achieved <b>Gold Medal</b> status and was awarded the prize for the <b>Best Model</b> for our <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling">extensive modeling</a> efforts as well as the prize for the <b>Best Part Collection</b> for our synthetic <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">promoter library</a>. Furthermore, we were nominated for the Best Health & Medicine Project, as well as the Best Wiki, Best Poster, and Best Basic Part.</p>
 +
 +
</p>
 +
 +
 +
</div>
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
 
<p></p>
<h3>We are proud to announce that we accomplished the following objectives:<h3>
+
<h3>We are proud to present the large variety of our further accomplishments:<h3>
 +
 
 
<h2>General Achievements</h2>
 
<h2>General Achievements</h2>
 
  
 
<ul>
 
<ul>
 +
<li><p>Our engineered <i>E.coli</i> can detect CTC based on their elevated lactate output. </p></li>
 +
 
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Description">novel system</a> for detection of circulating tumor cells in blood samples using genetically modified bacteria.</p></li>
 
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Description">novel system</a> for detection of circulating tumor cells in blood samples using genetically modified bacteria.</p></li>
  
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Genetic_circuit">genetic circuit</a> that integrates two different cancer specific signals (<a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">lactate </a>and <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module">AHL</a>)in an <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Combined_Model">AND gate</a>.</p></li>
+
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Genetic_circuit">genetic circuit</a> that integrates two different cancer specific signals (<a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">lactate </a>and <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module">AHL</a>) in an <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling">AND gate</a>.</p></li>
  
<li><p>We implemented a method to do single cell analysis of cancer cells by <a href="https://2015.igem.org/Team:ETH_Zurich/Design#System_Overview">expressing Annexin V in the <i> E. coli</i> outer membrane</a>, which enables them to selectively bind to apoptotic cancer cells.</p></li>
+
<li><p> We designed and validated a <a href=”https://2015.igem.org/Team:ETH_Zurich/Modeling#Combined_model_with_other_biological_features”>tight AND gate</a> with a clear binary behavior. </p></li>
 
</ul>
 
</ul>
  
 +
<h2>Experimental Achievements</h2>
 +
<ul>
  
 +
<li><p>We documented and submitted two new <a href="https://2015.igem.org/Team:ETH_Zurich/Basic_Part">basic parts</a> to the iGEM parts registry and created a <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">part collection</a> with 13 parts.</p></li>
  
 +
<li><p>We characterized <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_lacI-lldR_promoter">two newly designed hybrid promoters</a> and were able to show that one of our combined promoters, P<sub>lac-lldR</sub> (<a href="http://parts.igem.org/Part:BBa_K1847010">K1847010</a>), reacts in a clear AND gate fashion to a combination of lactate and IPTG. To our knowledge, combining these two elements has never been attempted before.</p></li>
  
 +
<li><p>We improved and characterized variants of the <i>E. coli</i> <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_LldR_promoter">lldPRD-operon promoter</a> based on the natural version (<a href="http://parts.igem.org/Part:BBa_K822000:Experience">BBa_K822000</a>), on which there is only a limited amount of information available in the Parts Registry and in the literature. The characterization of a <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_synthetic_promoter_library"> synthetic promoter library</a> yielded promoter variants that far outperform the wild type LldPRD promoter.</p></li>
  
 +
<li><p>We characterized the <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Quorum_sensing_module__influence_of_AHL_degradation">autoinducer inactivation enzyme (aiiA)</a>. With aiiA the quorum sensing system has 10 000x lower sensitivity.</p></li>
 +
<li><p>We characterized <a href="https://2015.igem.org/Team:ETH_Zurich/Results#_Experiments_involving_mammalian_cells_">sTRAIL</a> to induce apoptosis in cancer cells.</p></li>
  
 +
<li><p> We characterized the natural <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_natural_LldR_promoter">plldR promoter</a> and came up with the hypothesis that <a href ="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_natural_LldR_promoter">LldR has combined repression and activation</a>.</p></li>
  
  
 +
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Chip">chip</a> for future application of our MicroBeacon <i>E. coli</i>.</p></li>
  
 +
<li><p>We participated in the <a href="https://2015.igem.org/Team:ETH_Zurich/Interlab_study">interlab study</a>.</p></li>
  
 +
<li><p>Our experiments complied with the <a href="https://2015.igem.org/Team:ETH_Zurich/Safety">safety instructions</a> at the Department of Biosystems Science and Engineering <a href="http://www.bsse.ethz.ch/">D-BSSE</a> in Basel where our lab is situated.</p></li>
 +
</ul>
  
 +
<h2>Modeling Achievements</h2>
  
 +
<ul>
  
 +
<li><p>We separately modeled two different signals of our cancer detection system, the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">Lactate Module</a> and the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module"> AHL Module</a>.</p></li>
  
 +
<li><p>We defined and estimated <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Parameters">all relevant parameters for our models</a>.</p></li>
 +
 +
<li><p>We integrated the two modules into a <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Single-cell_Model">Combined Compartment Model</a> to simulate a logical AND gate.</p></li>
 +
 +
<li><p>To account for the diffusion and degradation of signaling molecules under real-world conditions we designed various <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Reaction-diffusion">Reaction-diffusion Models</a>.</p></li>
 +
 +
<li><p>We optimized our model by <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Experiments_Modelintegrating">integrating experimental data</a> gathered by the characterization of our LldR promoter constructs.</p></li>
 +
 +
<li><p>We showed that the successful detection of cancer cells with our system <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling#Conclusions">is feasible in principle</a>.</p></li>
 +
</ul>
 +
 +
<h2>Human Practices and Collaboration Achievements</h2>
 +
 +
<ul>
 +
<li><p>We interviewed several <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a> and integrated the insights we got into the design of our device.</p></li>
 +
 +
<li><p>We thought and performed a biological experiment with <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Education">primary school children</a> and learnt about their enthusiasm for science.</p></li>
 +
 +
<li><p>To get the publics attention we published two articles about iGEM and our project, one in a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Newspaper_Article">regional newspaper</a> and one in the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Polykum_Article">ETH-student magazine "Polykum"</a>. In addition we did a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Survey_Summary">survey in the streets of Basel</a> and asked the people about their perception of synthetic biology.</p></li>
 +
 +
<li><p>Talking to an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">ethics expert</a> helped us consider important ethical questions such, e.g. if it is defensible to use engineered organisms for diagnostic purposes.</p></li>
 +
 +
<li><p>We conducted an interview with the founder of a startup biotech company and discussed with him if MicroBeacon would be a promising <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">business idea</a>.</p></li>
 +
 +
<li><p>We talked to a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">patent expert</a> and learnt about patents in general and discussed about what parts of our system would be interesting to patent.</p></li>
 +
 +
<li><p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Stockholm">collaborated</a> with the team from <a href="https://2015.igem.org/Team:Stockholm"> Stockholm</a> by <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations">testing their constructs</a>.</p></li>
 +
 +
<li><p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, conducted a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#surveyEPFL">survey</a> together with the <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">troubleshooting advice</a> for their transformations.</p></li>
 +
</ul>
  
 
<h2>Medal Criteria</h2>
 
<h2>Medal Criteria</h2>
Line 65: Line 121:
 
<tr>
 
<tr>
  
  <td><p>We documented all the <a href="https://2015.igem.org/Team:ETH_Zurich/Parts#Newly_characterized">parts taken from the Registry of Standard Biological Parts</a>, of which two were redesigned and newly characterized.</p></td>
+
  <td><p>We documented all the <a href="https://2015.igem.org/Team:ETH_Zurich/Parts#Newly_characterized">parts taken from the Registry of Standard Biological Parts</a>, of which two (<a href="http://parts.igem.org/Part:BBa_C0160">BBa_C0160</a> and <a href="http://parts.igem.org/Part:BBa_K822000">BBa_K822000</a>) were redesigned and newly characterized.</p></td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Parts"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Parts"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
</tr>
 
</tr>
Line 80: Line 136:
 
<tr>
 
<tr>
  
  <td><p>We documented and submitted two new <a href="https://2015.igem.org/Team:ETH_Zurich/Basic_Part">basic parts</a> to the iGEM parts registry and created a <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">part collection</a> with 14 parts.</p></td>
+
  <td><p>We documented and submitted two new <a href="https://2015.igem.org/Team:ETH_Zurich/Basic_Part">basic parts</a> to the iGEM parts registry and created a <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">part collection</a> with 13 parts.</p></td>
 
  <td><a href="http://parts.igem.org/Part:BBa_K1847000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
  <td><a href="http://parts.igem.org/Part:BBa_K1847000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
</tr>
 
</tr>
Line 86: Line 142:
 
<tr>
 
<tr>
 
  <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/e/e8/ETH15_Silver_medal.png" width="70%"></img></td>
 
  <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/e/e8/ETH15_Silver_medal.png" width="70%"></img></td>
  <td><p>These new parts we also submitted to the iGEM Parts Registry. </p></td>
+
  <td><p>These <a href="https://2015.igem.org/Team:ETH_Zurich/Parts#Our_part_collection">13 new parts for our parts collection</a> we also submitted to the iGEM Parts Registry. </p></td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
</tr>
 
</tr>
Line 97: Line 153:
  
 
  <td><b>Our Human Practices Efforts:</b>
 
  <td><b>Our Human Practices Efforts:</b>
<p>We went to two different schools, thaught the children about what DNA is, performed experiments with them and published an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Newspaper_Article">article about it in the local newspaper</a>.</p>
+
<p>We visited two different elementary schools, thaught the children about what DNA is, performed experiments with them and published an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Newspaper_Article">article about it in the local newspaper</a>.</p>
  
<p>We told the ETH-student magazine <a href="http://www.vseth.ethz.ch/polykum/archiv#2014/2015">polykum</a> about iGEM and gave an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Polykum_Article">interview</a>.</p>
+
<p>We informed the ETH-student magazine <a href="http://www.vseth.ethz.ch/polykum/archiv#2014/2015">polykum</a> about iGEM and gave an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#Polykum_Article">interview</a>.</p>
  
 
<p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, conducted a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#surveyEPFL">survey</a> together with the <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">troubleshooting advice</a> for their transformations.</p>
 
<p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, conducted a <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#surveyEPFL">survey</a> together with the <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">troubleshooting advice</a> for their transformations.</p>
Line 109: Line 165:
 
  <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/9/9b/ETH15_Gold_medal.png" width="70%"></img></td>
 
  <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/9/9b/ETH15_Gold_medal.png" width="70%"></img></td>
 
  <td><b>More Human Practices Efforts:</b>
 
  <td><b>More Human Practices Efforts:</b>
<p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields, such as <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>,  <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">an expert from the ethics commission of the ETH Zurich</a>, the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">founder of a startup biotech company</a> or an  <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">expert in patents law</a> and <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">integrated their advice and ideas</a> into our <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Design">project design</a>.</p>
+
<p>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields: <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>,  <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">an expert from the ethics commission of the ETH Zurich</a>, the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">founder of a startup biotech company</a> as well as an  <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">expert in patent law</a> and <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">integrated their advice and ideas</a> into our <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">project design</a>.</p>
 
</td>
 
</td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
  <td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
Line 120: Line 176:
 
</tr>
 
</tr>
 
<tr>
 
<tr>
  <td><p>We Improved and characterized variants of the <i>E. coli</i> LldR promoter <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_LldR_promoter">lldPRD-operon</a>, on which there is only a limited amount of information present in the Parts Registry and in the literature.</p></td>
+
  <td><p>We Improved and characterized variants of the <i>E. coli</i> <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_LldR_promoter">lldPRD-operon promoter</a> based on the natural version (<a href="http://parts.igem.org/Part:BBa_K822000:Experience">BBa_K822000</a>), on which there is only a limited amount of information available in the Parts Registry and in the literature. The characterization of a <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_synthetic_promoter_library"> synthetic promoter library</a> yielded promoter variants that far outperform the wild type LldPRD promoter.</p></td>
 
  <td><a href="http://parts.igem.org/Part:BBa_K822000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
  <td><a href="http://parts.igem.org/Part:BBa_K822000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td>
 
</tr>
 
</tr>
Line 127: Line 183:
  
  
<h2>Further Experimental Achievements</h2>
 
<ul>
 
 
<li><p>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Chip">chip</a> for future application of our MicroBeacon <i>E. coli</i>.</p></li>
 
 
<li><p>We participated in the <a href="https://2015.igem.org/Team:ETH_Zurich/Interlab_study">interlab study</a>.</p></li>
 
 
<li><p>Our experiments complied with the <a href="https://2015.igem.org/Team:ETH_Zurich/Safety">safety instructions</a> at the Department of Biosystems Science and Engineering <a href="http://www.bsse.ethz.ch/">D-BSSE</a> in Basel where our lab is situated.</p></li>
 
</ul>
 
 
<h2>Modeling Achievements</h2>
 
 
<ul>
 
 
<li><p>We separately modeled two different signals of our cancer detection system, the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">Lactate Module</a> and the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module"> AHL Module</a>.</p></li>
 
 
<li><p>We defined and estimated <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Parameters">all relevant parameters for our models</a>.</p></li>
 
 
<li><p>We integrated the two modules into a <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Single-cell_Model">Combined Compartment Model</a> to simulate a logical AND gate.</p></li>
 
 
<li><p>To account for the diffusion and degradation of signaling molecules under real-world conditions we designed various <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Reaction-diffusion">Reaction-diffusion Models</a>.</p></li>
 
 
<li><p>We optimized our model by <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Experiments_Modelintegrating">integrating experimental data</a> gathered by the characterization of our LldR promoter constructs.</p></li>
 
 
<li><p>We showed that the successful detection of cancer cells with our system <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling#Conclusions">is feasible in principle</a>.</p></li>
 
  
 
</div>
 
</div>

Latest revision as of 18:51, 7 October 2015

"What I cannot create I do not understand."
- Richard Feynmann

Achievements

Awards and Medals

At the Giant Jamboree in Boston, MA, end of September 2105 our project MicroBeacon achieved Gold Medal status and was awarded the prize for the Best Model for our extensive modeling efforts as well as the prize for the Best Part Collection for our synthetic promoter library. Furthermore, we were nominated for the Best Health & Medicine Project, as well as the Best Wiki, Best Poster, and Best Basic Part.

We are proud to present the large variety of our further accomplishments:

General Achievements

  • Our engineered E.coli can detect CTC based on their elevated lactate output.

  • We designed a novel system for detection of circulating tumor cells in blood samples using genetically modified bacteria.

  • We designed a genetic circuit that integrates two different cancer specific signals (lactate and AHL) in an AND gate.

  • We designed and validated a tight AND gate with a clear binary behavior.

Experimental Achievements

Modeling Achievements

Human Practices and Collaboration Achievements

Medal Criteria

We registered for iGEM, had a great summer so far, and now we are looking forward to attending the Giant Jamboree!

Going for it!

We completed and submitted the Judging Form.

We created a description of our project in time.

We documented all the parts taken from the Registry of Standard Biological Parts, of which two (BBa_C0160 and BBa_K822000) were redesigned and newly characterized.

We are going to present a poster and give a talk at the Giant Jamboree.

Going for it!

We created this website for you to learn about every aspect of our iGEM project.

We documented and submitted two new basic parts to the iGEM parts registry and created a part collection with 13 parts.

These 13 new parts for our parts collection we also submitted to the iGEM Parts Registry.

We characterized two newly designed hybrid promoters and were able to show that one of our combined promoters, Plac-lldR (K1847010), reacts in a clear AND gate fashion to a combination of lactate and IPTG. To our knowledge, combining these two elements has never been attempted before.

Our Human Practices Efforts:

We visited two different elementary schools, thaught the children about what DNA is, performed experiments with them and published an article about it in the local newspaper.

We informed the ETH-student magazine polykum about iGEM and gave an interview.

We contributed to the Newsletters from Amoys team, met with the Darmstadt team, conducted a survey together with the EPFL and provided Colombias team with protocols and troubleshooting advice for their transformations.

More Human Practices Efforts:

We interviewed many different experts from various fields: medical doctors, an expert from the ethics commission of the ETH Zurich, the founder of a startup biotech company as well as an expert in patent law and integrated their advice and ideas into our project design.

We collaborated with the team from Stockholm by testing their constructs.

We Improved and characterized variants of the E. coli lldPRD-operon promoter based on the natural version (BBa_K822000), on which there is only a limited amount of information available in the Parts Registry and in the literature. The characterization of a synthetic promoter library yielded promoter variants that far outperform the wild type LldPRD promoter.

We would like to thank our sponsors